What is InnoCan Pharma?
InnoCan Pharma is dedicated to developing innovative non-opioid solutions for chronic pain management and wellness, serving both human and animal health markets. The company's strategic focus encompasses drug development, pre-clinical studies, and maintaining a robust regulatory pipeline. In addition to its pharmaceutical endeavors, InnoCan Pharma also offers wellness products infused with CBD, aiming to enhance overall well-being. The company's approach to pain management and wellness positions it as a key player in the evolving healthcare landscape, particularly for individuals seeking alternatives to traditional opioid treatments.
How much funding has InnoCan Pharma raised?
InnoCan Pharma has raised a total of $5.1M across 3 funding rounds:
Share Placement
$3.7M
Share Placement
$1.2M
Stock/Share Issuance
$200K
Share Placement (2020): $3.7M, investors not publicly disclosed
Share Placement (2023): $1.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $200K, investors not publicly disclosed
What's next for InnoCan Pharma?
The substantial enterprise-level funding and recent strategic investment provide InnoCan Pharma with the necessary capital to accelerate its research and development initiatives, expand its product portfolio, and strengthen its market presence. This infusion of backing is expected to fuel advancements in its non-opioid pain management solutions and CBD-infused wellness products. The company is poised to leverage this financial momentum to navigate its regulatory pathways and scale its operations, aiming to solidify its position as a leader in innovative health and wellness solutions.
See full InnoCan Pharma company page
